<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"
        xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
  <url>
    <loc>https://www.pharmanow.live/latest-news/viatris-tender-offer-acquire-pacira-biosciences</loc>
    <lastmod>2026-10-31T11:30:44+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-30T00:00:00+05:30</news:publication_date>
      <news:title>Viatris Launches $1.65B Tender Offer for Pacira BioSciences</news:title>
      <news:keywords>Viatris</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/https://newsroom.viatris.com/file.php/181193/Refreshed_Viatris_Logo_thumb.png?thumbnail=144</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/ema-prac-immunoglobulin-hypersensitivity-batch-review-2026</loc>
    <lastmod>2026-10-31T11:27:50+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-30T00:00:00+05:30</news:publication_date>
      <news:title>EMA PRAC Opens Class-Wide Review of Human Immunoglobulin Safety</news:title>
      <news:keywords>EMA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/ema-prac-human-normal-immunoglobulin-batch-hypersensitivity-review-202620261031112743.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-risk-based-inspection-model-cgmp-compliance-drug-manufacturing</loc>
    <lastmod>2026-10-31T11:18:48+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-30T00:00:00+05:30</news:publication_date>
      <news:title>FDA Reinforces Risk-Based Inspections Across U.S. Drug Plants</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/68750825-0b20-441b-a564-e1242f5a1283/3bc53589-71de-4e87-b905-c357be4f6c6f.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-frame-amtdp-continuous-manufacturing-ai-regulatory-framework</loc>
    <lastmod>2026-10-31T11:08:55+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-30T00:00:00+05:30</news:publication_date>
      <news:title>FDA Advances FRAME and AMTDP for AI-Driven Drug Manufacturing</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-frame-amtdp-continuous-ai-drug-manufacturing-regulatory-framework-202620261031110739.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/celularity-vesalius-longevity-labs-exclusive-peptide-api-manufacturing-deal</loc>
    <lastmod>2026-10-31T10:47:42+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-30T00:00:00+05:30</news:publication_date>
      <news:title>Celularity Signs Exclusive Deal with Vesalius Longevity Labs</news:title>
      <news:keywords>Celularity</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/celularity-vesalius-exclusive-peptual-peptide-api-manufacturing-deal-202620261031104315.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-ectd-v4-sample-submission-pathway-technical-filing-errors</loc>
    <lastmod>2026-10-30T12:10:15+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-29T00:00:00+05:30</news:publication_date>
      <news:title>FDA Opens eCTD v4.0 Sample Submission Pathway for Drug Sponsors</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-ectd-v4-sample-submission-pathway-technical-validation-filing-errors-202620261030120913.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-draft-guidance-drug-delivery-performance-characteristics-combination-products</loc>
    <lastmod>2026-10-30T12:06:51+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-29T00:00:00+05:30</news:publication_date>
      <news:title>FDA Draft Guidance Sets Drug Delivery Data Standards</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-drug-delivery-performance-combination-products-draft-guidance-202620261030113559.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-ectd-v4-forward-compatibility-october-2026</loc>
    <lastmod>2026-10-30T11:31:15+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-29T00:00:00+05:30</news:publication_date>
      <news:title>FDA Activates eCTD v4.0 Forward Compatibility for Drug Filings</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-ectd-v4-forward-compatibility-drug-submissions-october-202620261030113014.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/insmed-fda-priority-review-arikayce-snda-japan-brinsupri-ncfb-approval</loc>
    <lastmod>2026-10-30T11:27:44+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-29T00:00:00+05:30</news:publication_date>
      <news:title>Insmed Gains FDA Priority Review for ARIKAYCE sNDA</news:title>
      <news:keywords>Insmed</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/insmed-arikayce-fda-priority-review-brinsupri-japan-launch-202620261030112728.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-confirms-rx7-articulaciones-hidden-diclofenac-dexamethasone</loc>
    <lastmod>2026-10-30T11:23:43+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-29T00:00:00+05:30</news:publication_date>
      <news:title>FDA Confirms RX7 Articulaciones Contains Undeclared Drugs</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-rx7-articulaciones-hidden-diclofenac-dexamethasone-202620261030112244.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-confirms-ort-flx-undeclared-diclofenac-dexamethasone-methocarbamol</loc>
    <lastmod>2026-10-30T11:11:44+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-29T00:00:00+05:30</news:publication_date>
      <news:title>FDA Confirms Three Undeclared Drugs in Ort-Flx Pain Product</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-ort-flx-undeclared-diclofenac-dexamethasone-methocarbamol-202620261030111001.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/azora-therapeutics-appoints-executive-team-at177-phase-1-ulcerative-colitis-2027</loc>
    <lastmod>2026-10-30T11:03:10+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-29T00:00:00+05:30</news:publication_date>
      <news:title>Azora Therapeutics Appoints New Executive Team to Advance AT177</news:title>
      <news:keywords>Azora</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/azora-therapeutics-executive-team-at177-ulcerative-colitis-phase-1-202720261030110132.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-biosimilar-approval-tracker-2024-2026</loc>
    <lastmod>2026-10-30T10:49:15+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-29T00:00:00+05:30</news:publication_date>
      <news:title>FDA Biosimilar Tracker: 30+ Products Cleared Since Mid-2024</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-biosimilar-approval-tracker-2024-2026-30-plus-products20261030104748.webp</image:loc>
    </image:image>
  </url>
</urlset>